Drugs / Pn-MAPS30plus
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07406347 | Jan 2027 → Oct 2028 expected | bacterial pneumonia | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07406334 | May 2026 → Feb 2027 expected | bacterial pneumonia | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07428759 | Mar → Dec 2026 expected | bacterial pneumonia | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07105722 | Aug 2025 → May 2026 | bacterial pneumonia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pn-MAPS30plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07406334 ↗ |
| Modality | Vaccine | “investigational pneumococcal vaccine named Pn-MAPS30plus” NCT07105722 ↗ |
| Route | Intramuscular | “The Pn-MAPS30plus vaccine will be administered intramuscularly.” NCT07105722 ↗ |